Salud financiera de hoja de balance de Resonance Health

Salud financiera controles de criterios 6/6

Resonance Health tiene un patrimonio de los accionistas total de A$9.8M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$10.9M y A$1.1M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$5.90m
Patrimonio	AU$9.84m
Total pasivo	AU$1.08m
Activos totales	AU$10.92m

Actualizaciones recientes sobre salud financiera

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Mar 01

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Jan 15

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Nov 22

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$7.3M) de RHT superan a sus pasivos a corto plazo (A$889.7K).

Pasivo a largo plazo: Los activos a corto plazo de RHT (A$7.3M) superan a sus pasivos a largo plazo (A$193.7K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RHT está libre de deudas.

Reducción de la deuda: RHT no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RHT tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: RHT dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 31.8% cada año

Salud financiera de hoja de balance de Resonance Health

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

New minor risk - Share price stability

New minor risk - Share price stability

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in FY 2022)

New minor risk - Financial data availability

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)

Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

FerriScan Now Available on 3 Tesla (3T) MRI Machines

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited Receives United States CPT Code Confirmation for Liversmart

Resonance Health Limited Announces US FDA Clearance for LiverSmart

Resonance Health Ltd Provides Update on its Antisense Oligonucleotide Project for Treating Viral Hepatitis

Resonance Health Limited Announces Filing of Two Patent Applications

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Resonance Health Ltd announces R&D Molecular Medicine ASON Project Results of Dosing Study

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Chief Executive Officer Alison Laws has left the company

Resonance Health Limited Announces Filing of Patent Application

Resonance Health Limited Provides Update on Its Antisense Oligonucleotide R&D Project for Treating Liver Related Diseases

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Resonance Health Ltd HepaFat-AI Receives CE Marking

Resonance Health Ltd Receives Australian Therapeutic Goods Administration Approval for HepaFat-AI

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Resonance's HepaFat-AI Incorporated into Blackford Analysis

New 90-day high: AU$0.28

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Resonance Health Ltd Develops New Artificial Intelligence Tool for the Automated Review of Chest Computed Tomography Scans of Patients with Suspected Pulmonary Embolism

Full year earnings released - AU$0.0017 loss per share

Full year earnings released - AU$0.0017 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera